11.09
+0.69(+6.63%)
Currency In USD
| Previous Close | 10.4 |
| Open | 10.55 |
| Day High | 11.22 |
| Day Low | 10.38 |
| 52-Week High | 29.56 |
| 52-Week Low | 8.18 |
| Volume | 2.46M |
| Average Volume | 1.09M |
| Market Cap | 852.58M |
| PE | -3.73 |
| EPS | -2.97 |
| Moving Average 50 Days | 9.51 |
| Moving Average 200 Days | 12.21 |
| Change | 0.69 |
If you invested $1000 in Nurix Therapeutics, Inc. (NRIX) since IPO date, it would be worth $583.38 as of October 26, 2025 at a share price of $11.09. Whereas If you bought $1000 worth of Nurix Therapeutics, Inc. (NRIX) shares 3 years ago, it would be worth $918.81 as of October 26, 2025 at a share price of $11.09.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock
GlobeNewswire Inc.
Oct 22, 2025 11:20 AM GMT
SAN FRANCISCO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology a
Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia
GlobeNewswire Inc.
Oct 22, 2025 10:00 AM GMT
600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Phase 2 DAYBreak trial initiated for potential Accelerated Approval New preclinical dat
Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress
GlobeNewswire Inc.
Oct 18, 2025 7:00 AM GMT
NX-1607 demonstrated on-target peripheral immune activation characteristic of an active immune-oncology agent with a novel immune checkpoint mechanism distinct from PD-1/PD-L1 therapies NX-1607 demonstrated evidence of monotherapy anti-tumor activity